BRIM Biotechnology, Inc announced an equity round of funding on January 5, 2020. The transaction will include participation from China Grand Pharmaceutical and Healthcare Holdings Limited (SEHK:512). The investor will acquire the right for appointment of a new director.

The transaction is subject to approval of shareholders in the general meeting of the company.